PD26-06 ADJUVANT CHEMOTHERAPY PLUS RADIOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR LOCALLY ADVANCED BLADDER CANCER AFTER RADICAL CYSTECTOMY

医学 膀胱切除术 膀胱癌 放射治疗 化疗 随机对照试验 癌症 肿瘤科 内科学 普通外科 泌尿科
作者
John Ernandez,Sumedh Kaul,Aaron Fleishman,Ruslan Korets,Peter Chang,Andrew Wagner,Simon Kim,Joaquim Bellmunt,Irving Kaplan,Aria F. Olumi,Boris Gershman
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:207 (Supplement 5)
标识
DOI:10.1097/ju.0000000000002574.06
摘要

You have accessJournal of UrologyCME1 May 2022PD26-06 ADJUVANT CHEMOTHERAPY PLUS RADIOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR LOCALLY ADVANCED BLADDER CANCER AFTER RADICAL CYSTECTOMY John Ernandez, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Simon Kim, Joaquim Bellmunt, Irving Kaplan, Aria Olumi, and Boris Gershman John ErnandezJohn Ernandez More articles by this author , Sumedh KaulSumedh Kaul More articles by this author , Aaron FleishmanAaron Fleishman More articles by this author , Ruslan KoretsRuslan Korets More articles by this author , Peter ChangPeter Chang More articles by this author , Andrew WagnerAndrew Wagner More articles by this author , Simon KimSimon Kim More articles by this author , Joaquim BellmuntJoaquim Bellmunt More articles by this author , Irving KaplanIrving Kaplan More articles by this author , Aria OlumiAria Olumi More articles by this author , and Boris GershmanBoris Gershman More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002574.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Survival for patients with locally advanced bladder cancer following radical cystectomy (RC) remains poor. Although adjuvant chemotherapy (AC) is standard of care, one small randomized trial has suggested a potential disease-free survival benefit with the addition of post-operative radiotherapy (PORT). We therefore examined the association of PORT with overall survival (OS) in patients with locally advanced bladder cancer after RC. METHODS: Using a completed phase 2 trial to inform the design of the present study, we conducted observational analyses to emulate a hypothetical target trial of patients aged 18-79 years with pT3-4 Nany M0 or pTany N1-3 M0 urothelial carcinoma of the bladder following RC who were treated with AC (multiagent chemotherapy within 3 months of RC) with or without PORT (≥45 Gy to the pelvis) from 2006-2015 in the National Cancer Database. Patients who received preoperative chemotherapy or radiotherapy were excluded. The associations of treatment arm with OS were evaluated using multivariable Cox regression. RESULTS: A total of 1,684 patients were included, of whom 66 underwent PORT+AC and 1,618 AC alone. Compared to patients treated with AC alone, those treated with PORT+AC were more likely to have pT4 disease (52% vs 26%; p<0.01), have positive surgical margins (44% vs 17%; p<0.01), and be treated at a non-academic facility (75% vs 53%; p<0.01). Crude 3- and 5-year OS were 31% and 19% for PORT+AC versus 48% and 36% for AC alone (p=0.01). Adjusted 3- and 5-year OS were 44% and 33% for PORT+AC versus 48% and 36% for AC alone (p=0.49). After adjusting for baseline characteristics including pathologic features, PORT+AC was not associated with improved OS compared to AC alone (HR 1.11; 95% CI 0.82-1.51; Figure 1). CONCLUSIONS: Although infrequently utilized, the present analyses suggest that the addition of radiotherapy to AC is not associated with improved OS in locally advanced bladder cancer. These results highlight the need for prospective trials to better define the potential benefits from PORT with regard to symptomatic progression and oncologic outcomes. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e489 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information John Ernandez More articles by this author Sumedh Kaul More articles by this author Aaron Fleishman More articles by this author Ruslan Korets More articles by this author Peter Chang More articles by this author Andrew Wagner More articles by this author Simon Kim More articles by this author Joaquim Bellmunt More articles by this author Irving Kaplan More articles by this author Aria Olumi More articles by this author Boris Gershman More articles by this author Expand All Advertisement PDF DownloadLoading ...

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
欧阳懿完成签到,获得积分10
刚刚
Yang完成签到,获得积分10
1秒前
XYN1完成签到,获得积分10
1秒前
yizhiGao完成签到,获得积分0
2秒前
天天快乐的应助被Hohowinnie采纳,获得10
2秒前
5秒前
娜娜子完成签到 ,获得积分10
5秒前
5秒前
Meme发布了新的文献求助10
6秒前
6秒前
7秒前
Orange的应助被迷路书萱采纳,获得10
7秒前
充电宝的应助被wgt采纳,获得10
7秒前
8秒前
8秒前
Winky发布了新的文献求助10
9秒前
冷酷随阴完成签到,获得积分20
9秒前
慕青的应助被笑点低的火龙果采纳,获得10
12秒前
12秒前
老鼎发布了新的文献求助10
12秒前
13秒前
FashionBoy的应助被科研通管家采纳,获得10
13秒前
Owen的应助被科研通管家采纳,获得10
13秒前
13秒前
大模型的应助被科研通管家采纳,获得10
13秒前
13秒前
完美世界的应助被科研通管家采纳,获得10
13秒前
13秒前
英俊的铭的应助被科研通管家采纳,获得10
14秒前
香蕉觅云的应助被科研通管家采纳,获得10
14秒前
小二郎的应助被科研通管家采纳,获得10
14秒前
纯真忆秋发布了新的文献求助30
14秒前
15秒前
在水一方的应助被esther颖采纳,获得10
15秒前
superchen发布了新的文献求助10
16秒前
17秒前
Dumift完成签到,获得积分10
18秒前
温柔傲芙发布了新的文献求助20
18秒前
亨特Bao完成签到,获得积分10
18秒前
20秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Rosenblum, Global Change Biology 800
The Dawn of Philology 520
Organizational Behavior 510
Production Logging: Theoretical and Interpretive Elements 400
A primer on partial least squares structural equation modeling (PLS-SEM) (4th ed.) 310
中国器官捐献和移植发展报告(2024) 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 有机化学 化学工程 内科学 物理 生物化学 复合材料 催化作用 细胞生物学 人工智能 心理学 无机化学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 7821313
求助须知:如何正确求助?哪些是违规求助? 9348419
关于积分的说明 20547345
捐赠科研通 7414201
什么是DOI,文献DOI怎么找? 3333022
关于科研通互助平台的介绍 2478978
邀请新用户注册赠送积分活动 2353187